证券日报网讯8月5日晚间，迈威生物发布公告称，公司拟将回购价格上限由人民币35.00元/股(含)调整 为人民币48.00元/股(含)。 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 报告显示，2024年A股上市公司所有财务总监平均年薪为81.48万元。而395家生物医药行业上市公司 CFO平均薪酬跃升至91.97万元（中位数约74.23万元），超出全市场均值达12.8%。 聚焦上海地区，39家生物医药（申万一级）企业CFO总薪酬4442.62万元，其平均年薪进一步跃升至 113.91万元（中位数约102.20万元），较市场均值高出39.8%，显著展现区域与行业的双重溢价效应。 迈威生物CFO薪酬排名第三，个人履历显赫 在上海医药生物领域CFO前十强中，迈威生物华俊成为焦点。 根据公开信息，华俊2024年薪酬达277.71万元。需注意的是，2023年度统计的CFO薪酬159.21万元为 2023年6月上任的财务负责人华俊收入，不包括离职的叶茵薪酬。 年报显示，2024年华俊薪酬较2023年报表数据上升118.5万元，增幅74.43%。 新浪财经《2024年度A股CFO数据报告》最新披露，医药生物行业CFO薪酬显著高于A股平均水 ...

Economic News - The Ministry of Commerce reported that China's service trade import and export totaled 38,872.6 billion yuan in the first half of the year, a year-on-year increase of 8.0% [1] - The China Logistics and Purchasing Federation announced that the logistics industry prosperity index for July was 50.5, indicating continued expansion but a slight slowdown in growth [1] - The People's Bank of China and six other departments stated that by 2027, the financial system supporting the high-end, intelligent, and green development of manufacturing will be basically mature [1] - The National Healthcare Security Administration announced that 55 types of drugs will be included in the 11th batch of centralized procurement, with rational bidding from enterprises [1] - The Supreme People's Court reported that 1,156 cases of medical insurance fraud were concluded in 2024, recovering over 400 million yuan in losses [1] - The Shanghai Stock Exchange revealed that the number of new A-share accounts in July increased by 71% year-on-year, reflecting a recovery in the A-share market [1] Company News - China Shipbuilding Industry Corporation plans to absorb and merge China Shipbuilding Heavy Industry Company, leading to the latter's delisting [5] - Green通科技 intends to use 45,040 million yuan of raised funds to acquire a 46.92% stake and invest 8,000 million yuan in Damo Semiconductor, resulting in a 51% stake in the company [5] - Shanghai Washba established a joint venture with Yuyuan Rare Earth New Materials Co., with a registered capital of 200 million yuan [5] - Maiwei Bio's chairman received an administrative penalty from the China Securities Regulatory Commission for suspected short-term trading [5] Bond Market Analysis - The Ministry of Finance announced that starting August 8, 2025, interest income from newly issued government bonds will be subject to VAT, reversing previous exemptions [7] - The policy aims to narrow the tax burden differences in the bond market and is expected to help alleviate fiscal pressure, as public budget revenue decreased by 0.3% year-on-year in the first half of the year [8] - The impact of the VAT restoration on 10-year government bonds is estimated to be around 10 basis points for self-operated accounts and 5 basis points for asset management products [9] - The new tax policy may lead to a widening of the yield spread between new and old bonds, with credit bonds potentially becoming more attractive [10] - The bond market is expected to experience fluctuations in the short term, with a projected yield range of 1.6% to 1.8% [12]

2024年1至12月份，迈威生物的营业收入构成为：医药制造行业占比99.92%，其他业务占比0.08%。 （文章来源：每日经济新闻） 迈威生物（SH 688062，收盘价：35.52元）8月5日晚间发布公告称，截至2025年7月31日，公司尚未实 施本次股份回购，公司后续将根据市场情况择机实施本次回购计划。 ...

经济观察网2025年8月5日，迈威生物(688062)发布公告，公司拟2500万元至5000万元回购股份，回购价 格不超过48元/股。 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-041 迈威（上海）生物科技股份有限公司 关于调整回购股份价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为保证回购股份方案顺利实施，迈威（上海）生物科技股份有限公司（以 下简称"公司"）拟将回购价格上限由人民币 35.00 元/股（含）调整为人民币 48.00 元/股（含）。 除上述调整回购股份价格上限外，回购方案的其他内容不变。 本次调整回购股份价格上限事项无需提交公司股东大会审议。 一、 回购股份的基本情况和实施进展 公司于 2025 年 6 月 26 日召开第二届董事会第十九次会议，审议通过了《关 于以集中竞价交易方式回购股份方案的议案》，同意公司通过上海证券交易所交 易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股份。 回购价格不超过人民币 35.00 元/股（含），回购资金总额不低于人民币 2,500 万 元（含），不超过人民币 5,000 万元（含），回购期限自董事会审议通过本次回 购方案之日起 ...

| 回购方案首次披露日 | 2025/6/27 | | --- | --- | | 回购方案实施期限 | 年 月 日~2026 年 月 日 2025 6 26 6 25 | | 预计回购金额 | 2,500万元~5,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 0万股 | | 累计已回购股数占总股本比例 | 0% | | 累计已回购金额 | 0万元 | | 实际回购价格区间 | 0元/股~0元/股 | 一、 回购股份的基本情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开第二届董事会第十九次会议，审议通过了《关于以集中竞价交易方式回购 股份方案的议案》，同意公司使用自有资金和/或股票回购专项贷款通过上海证券交 易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股） 股票，本次回购的股份将用于员工持股计划或股权激励，回购价格不超过人民币 35.00 元/股（含），回购资金总额不低于人民币 2,500 万元（含），不 ...

人民财讯8月5日电，迈威生物(688062)8月5日晚间公告，公司拟将回购价格上限由35元/股(含)调整为48 元/股(含)。 ...

格隆汇8月5日丨迈威生物(688062.SH)公布，截至2025年7月31日，公司尚未实施本次股份回购，公司后 续将根据市场情况择机实施本次回购计划。 ...

Core Viewpoint - The collaboration between Maiwei Biopharma and Qilu Pharmaceutical reflects a new trend in the biopharmaceutical industry, where innovative drug companies focus on R&D while traditional pharmaceutical companies handle commercialization through technology licensing [1][2] Company Summary - Maiwei Biopharma has signed a technology licensing agreement with Qilu Pharmaceutical for the injectable drug Aggrastat α (trade name: Mai Li Sheng), granting exclusive rights for development, production, improvement, utilization, and commercialization in Greater China [1] - The agreement includes an upfront payment and milestone payments totaling up to 500 million RMB, along with royalties based on net sales of the licensed product [1] Product Summary - Aggrastat α is a recombinant human serum albumin-granulocyte colony-stimulating factor (G-CSF) fusion protein, designed to reduce the incidence of infections in adult patients undergoing chemotherapy that causes febrile neutropenia [1][2] - This product is the first approved drug in China utilizing albumin fusion technology, which enhances the drug's half-life and reduces dosing frequency, thereby improving patient compliance [2] - The production process utilizes a Pichia pastoris expression system, simplifying manufacturing and improving product uniformity compared to chemically modified long-acting products [2] Industry Trend - The partnership exemplifies a model that allows innovative drugs to reach patients more quickly and cost-effectively, contributing to a biopharmaceutical ecosystem characterized by specialized R&D, large-scale production, and refined commercialization [2]